Description
PSB 0739 is a highly potent, direct-acting and reversible P2Y12 receptor antagonist (Ki = 24.9 nM). Unlike clopidogrel, it does not require bioactivation. P2Y12 receptors regulate CFA-induced hyperalgesia and the local inflammatory response, and platelet P2Y12 receptors contribute to these effects in the chronic inflammation phase